

Publication (2018~)

2023

1. Yonezawa T, Suzuki A, Fukumitsu K, Katano T, Kako H, Ishii M, Niimi A, Imaizumi K, Sakamoto K, Omote N. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment? *Respiratory Medicine Case Reports* 2023, 43:101857.
2. Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials. *JAMA* 2023, 329(18):1567-1578.
3. Kataoka K, Oda K, Takizawa H, Ogura T, Miyamoto A, Inoue Y, Akagawa S, Hashimoto S, Kishaba T, Sakamoto K. Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy. *Scientific Reports* 2023, 13(1):13664.
4. Kataoka K, Nishiyama O, Ogura T, Mori Y, Kozu R, Arizono S, Tsuda T, Tomioka H, Tomii K, Sakamoto K. Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial. *Thorax* 2023.
5. Fukutani E, Wakahara K, Nakamura S, Yokoi E, Yoshimi A, Miyazaki M, Nakamura M, Shindo Y, Sakamoto K, Okachi S. Inhalation adherence for asthma and COPD improved during the COVID-19 pandemic: a questionnaire survey at a university hospital in Japan. *Journal of Asthma* 2023:1-12.

2022.

6. Yuan Y, Cosme Jr C, Adams TS, Schupp J, Sakamoto K, Xylourgidis N, Ruffalo M, Li J, Kaminski N, Bar-Joseph Z. CINS: Cell Interaction Network inference from Single cell expression data. *PLOS Computational Biology* 2022, 18(9):e1010468.
7. Goto Y, Sakamoto K, Fukihara J, Suzuki A, Omote N, Ando A, Shindo Y, Hashimoto N. COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review. *Front Med (Lausanne)* 2022, 9:815924.
8. Suzuki A, Sakamoto K, Nakahara Y, Enomoto A, Hino J, Ando A, Inoue M, Shiraki Y, Omote N, Kusaka M. BMP3b is a novel antifibrotic molecule regulated by meflin in lung fibroblasts. *American Journal of Respiratory Cell and Molecular Biology* 2022, 67(4):446-458.
9. Omote N, Kanemitsu Y, Inoue T, Yonezawa T, Ichihashi T, Shindo Y, Sakamoto

K, Ando A, Suzuki A, Niimi A. Successful treatment with high-dose steroids for acute exacerbation of idiopathic pulmonary fibrosis triggered by COVID-19. *Internal Medicine* 2022, 61(2):233-236.

10. Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H. DOCK2 is involved in the host genetics and biology of severe COVID-19. *Nature* 2022, 609(7928):754-760.

11. Furukawa T, Oyama S, Yokota H, Kondoh Y, Kataoka K, Johkoh T, Fukuoka J, Hashimoto N, Sakamoto K, Shiratori Y. A comprehensible machine learning tool to differentially diagnose idiopathic pulmonary fibrosis from other chronic interstitial lung diseases. *Respirology* 2022, 27(9):739-746.

12. Fukihara J, Maiolo S, Kovac J, Sakamoto K, Wakahara K, Hashimoto N, Reynolds PN. Overexpression of bone morphogenetic protein receptor type 2 suppresses transforming growth factor β -induced profibrotic responses in lung fibroblasts. *Experimental Lung Research* 2022, 48(1):35-51.

2021.

13. Teramachi R, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Yokoyama T, Furukawa T, Yagi M, Sakamoto K, Hashimoto N. Impact of post-capillary pulmonary hypertension on mortality in interstitial lung disease. *Respiratory Investigation* 2021, 59(3):342-349.

14. Suzuki A, Sakaguchi H, Sakamoto K, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Sugiyama Y. The effect of pirfenidone on the prescription of antibiotics and antitussive drugs in patients with idiopathic pulmonary fibrosis: a post hoc exploratory analysis of phase III clinical trial. *Chest* 2021, 160(4):1372-1376.

15. Sakamoto K, Furukawa T, Yamano Y, Kataoka K, Teramachi R, Walia A, Suzuki A, Inoue M, Nakahara Y, Ryu C. Serum mitochondrial DNA predicts the risk of acute exacerbation and progression of idiopathic pulmonary fibrosis. *European Respiratory Journal* 2021, 57(1).

16. Omote N, Sakamoto K, Li Q, Schupp JC, Adams T, Ahangari F, Chioccioli M, DeIuliis G, Hashimoto N, Hasegawa Y. Long noncoding RNA TINCR is a novel regulator of human bronchial epithelial cell differentiation state. *Physiological Reports* 2021, 9(3):e14727.

17. Nakahara Y, Hashimoto N, Sakamoto K, Enomoto A, Adams TS, Yokoi T, Omote N, Poli S, Ando A, Wakahara K. Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis. *European Respiratory Journal* 2021, 58(6).

18. Inoue M, Sakamoto K, Suzuki A, Nakai S, Ando A, Shiraki Y, Nakahara Y,

Omura M, Enomoto A, Nakase I. Size and surface modification of silica nanoparticles affect the severity of lung toxicity by modulating endosomal ROS generation in macrophages. *Particle and fibre toxicology* 2021, 18(1):1-20.

19. Hashimoto N, Wakahara K, Sakamoto K. The importance of appropriate diagnosis in the practical management of chronic obstructive pulmonary disease. *Diagnostics* 2021, 11(4):618.

2020.

20. Suzuki A, Kondoh Y, Brown KK, Johkoh T, Kataoka K, Fukuoka J, Kimura T, Matsuda T, Yokoyama T, Fukihara J. Acute exacerbations of fibrotic interstitial lung diseases. *Respirology* 2020, 25(5):525-534.

21. Sakamoto K, Fukihara J, Morise M, Hashimoto N. Clinical burden of immune checkpoint inhibitor-induced pneumonitis. *Respiratory Investigation* 2020, 58(5):305-319.

22. Omote N, Matsuda N, Hashimoto N, Nishida K, Sakamoto K, Ando A, Nakahara Y, Nishikimi M, Higashi M, Matsui S. High-flow nasal cannula therapy for acute respiratory failure in patients with interstitial pneumonia: a retrospective observational study. *Nagoya Journal of Medical Science* 2020, 82(2):301.

23. Murakami Y, Sakamoto K, Okumura Y, Suzuki A, Mii S, Sato M, Yokoi T, Hashimoto N, Hasegawa Y. Acute Exacerbation of Pleuroparenchymal Fibroelastosis Secondary to Allogenic Hematopoietic Stem Cell Transplantation. *Internal Medicine* 2020, 59(21):2737-2743.

24. Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N. Reply to “Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors”. *Clinical Lung Cancer* 2020, 21(3):e205.

25. Arizono S, Furukawa T, Taniguchi H, Sakamoto K, Kimura T, Kataoka K, Ogawa T, Watanabe F, Kondoh Y. Supplemental oxygen improves exercise capacity in IPF patients with exertional desaturation. *Respirology* 2020, 25(11):1152-1159.

2019.

26. Suzuki A, Kondoh Y, Swigris JJ, Matsuda T, Kimura T, Kataoka K, Ando M, Hashimoto N, Sakamoto K, Hasegawa Y. Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease. *Respiratory Medicine* 2019, 150:15-20.

27. Okada Y, Hashimoto N, Iwano S, Kawaguchi K, Fukui T, Sakamoto K, Wakai K,

Yokoi K, Hasegawa Y. Renewed Japanese spirometric reference variables and risk stratification for postoperative outcomes in COPD patients with resected lung cancer. *Nagoya Journal of Medical Science* 2019, 81(3):427.

28. Fukihara J SK, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. *Clin Lung Cancer* 2019, 20(6):442-450.

29. Ando A, Hashimoto N, Sakamoto K, Omote N, Miyazaki S, Nakahara Y, Imaizumi K, Kawabe T, Hasegawa Y. Repressive role of stabilized hypoxia inducible factor 1 α expression on transforming growth factor β - induced extracellular matrix production in lung cancer cells. *Cancer science* 2019, 110(6):1959-1973.

2018.

30. Yamano Y, Taniguchi H, Kondoh Y, Ando M, Kataoka K, Furukawa T, Johkoh T, Fukuoka J, Sakamoto K, Hasegawa Y. Multidimensional improvement in connective tissue disease - associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low - dose prednisone and tacrolimus. *Respirology* 2018, 23(11):1041-1048.

31. Teramachi R, Kondoh Y, Kataoka K, Taniguchi H, Matsuda T, Kimura T, Yokoyama T, Yamano Y, Furukawa T, Sakamoto K. Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis. *Respiratory medicine* 2018, 143:147-152.

32. Suzuki A, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, Matsuda T, Yokoyama T, Sakamoto K, Hasegawa Y. Prognostic evaluation by oxygenation with positive end - expiratory pressure in acute exacerbation of idiopathic pulmonary fibrosis: a retrospective cohort study. *The Clinical Respiratory Journal* 2018, 12(3):895-903.

33. Suzuki A, Kondoh Y, Swigris JJ, Ando M, Kimura T, Kataoka K, Yamano Y, Furukawa T, Numata M, Sakamoto K. Performance of the St George' s Respiratory Questionnaire in patients with connective tissue disease - associated interstitial lung disease. *Respirology* 2018, 23(9):851-859.

34. Hashimoto N, Ando A, Iwano S, Sakamoto K, Okachi S, Matsuzaki A, Okada Y, Wakai K, Yokoi K, Hasegawa Y. Thin-section computed tomography-determined usual interstitial pneumonia pattern affects the decision-making process for resection in newly diagnosed lung cancer patients: a retrospective study. *BMC Pulmonary Medicine* 2018, 18(1):1-9.

35. Furukawa T, Kondoh Y, Taniguchi H, Yagi M, Matsuda T, Kimura T, Kataoka K,

Johkoh T, Ando M, Hashimoto N. A scoring system to predict the elevation of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis. *European Respiratory Journal* 2018, 51(1).